Patent ID: 6599699
Filing Date: 2003-07-29
Classification: A61K,A61P,C07K

Abstract:
A method for determining presence of cancer which is characterized by expression of a nucleic acid molecule which encodes a tumor rejection antigen precursor, wherein (i) said tumor rejection antigen precursor is processed, intracellularly, to a tumor rejection antigen that forms a complex with an HLA molecule and is recognized by a cytolytic T cell specific for said complex and (ii) said nucleic acid molecule has a complementary sequence which hybridizes, under stringent conditions defined as four washes in 2Ã—SSC, 0.1% SDS, at 65Â° C., and one 30 minute wash in 0.1Ã—SSC, 0.1% SDS to either SEQ ID NO: 11 or SEQ ID NO: 12, comprising contacting a sample taken from a subject with a nucleic acid molecule which hybridizes to said nucleic acid molecule under said stringent conditions to determine expression of said nucleic acid molecule, wherein expression of said nucleic acid molecule is indicative of said cancer.